On December 31, 2020, China Sinopharm’s COVID-19 inactivated vaccine was approved by the State Food and Drug Administration to be listed with conditions. according to the existing data, its protection ratio was 79.34%, and it is an unity of security, effectiveness, accessibility and affordability.